

available at www.sciencedirect.com

ScienceDirect

www.elsevier.com/locate/molonc

Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity

Q11 Valérie Lang^a, Chiara Pallara^b, Amaia Zabala^c, Sofia Lobato-Gil^a,
 Fernando Lopitz-Otsoa^c, Rosa Farrás^d, Roland Hjerpe^{c,1},
 Monica Torres-Ramos^{c,2}, Lorea Zabaleta^a, Christine Blattner^e,
 Ronald T. Hay^f, Rosa Barrio^c, Arkaitz Carracedo^{c,g,h},
 Juan Fernandez-Recio^b, Manuel S. Rodríguez^{a,*},
 Fabienne Aillet^a

^aUbiquitylation and Cancer Molecular Biology Laboratory, Inbiomed, Mikeletegi 81, San Sebastián-Donostia 20009, Gipuzkoa, Spain

^bJoint BSC-IRB Research Program in Computational Biology, Life Sciences Department, Barcelona Supercomputing Center, Carrer Jordi Girona 29, 08034 Barcelona, Spain

^cCIC bioGUNE, Ed 801A Parque Tecnológico de Bizkaia, 48160 Derio, Bizkaia, Spain

^dCentro de Investigación Príncipe Felipe, Eduardo Primo Yúfera 3, 46012 Valencia, Spain

^eKarlsruher Institute of Technology, Institute of Toxicology and Genetics, Fritz-Erler-Straße 23, 76133 Karlsruhe, Germany

^fCenter for Interdisciplinary Research, School of Life Sciences, University of Dundee, Dow Street, DD15EH Scotland, United Kingdom

^gIkerbasque, Basque Foundation for Science, 48011 Bilbao, Spain

^hBiochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), P.O. Box 644, E-48080 Bilbao, Spain

ARTICLE INFO

ABSTRACT

Article history:

Received 30 October 2013

Received in revised form

19 March 2014

The tumor suppressor p53 regulates the expression of genes involved in cell cycle progression, senescence and apoptosis. Here, we investigated the effect of single point mutations in the oligomerization domain (OD) on tetramerization, transcription, ubiquitylation and stability of p53. As predicted by docking and molecular dynamics simulations, p53 OD mutants show functional defects on transcription, Mdm2-dependent ubiquitylation and 26S

Abbreviations: OD, Oligomerization Domain; Bax, Bcl2-associated X protein; Bcl-XL, B-cell lymphoma-extralarge; PUMA, p53-regulated Modulator of Apoptosis; Noxa, Noxious stress induced protein; Bid, BH3 interacting domain death agonist; FAS/CD95, Fas (TNF receptor superfamily, member 6); p21, Chromosome 6p21.2 located Cyclin-dependent kinase inhibitor 1A; E2F1, E2F transcription factor 1; Mdm2, Mouse double minute 2 homolog ubiquitin ligase; PCNA, Proliferating Cell Nuclear Antigen; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; 14.3.3 σ , 14-3-3 sigma protein eluted in the 14th fraction of bovine brain homogenate and migrating on position 3.3 after electrophoresis; MD, Molecular dynamics; FTDOCK, FFT-based docking program; ADR, Adriamycin; RMSD, Root mean square deviation.

* Corresponding author. Tel.: +34 943 309 064; fax: +34 943 308 222.

E-mail addresses: vlang@inbiomed.org (V. Lang), chiara.pallara@bsc.es (C. Pallara), azabala@cicbiogune.e (A. Zabala), slobato@inbiomed.org (S. Lobato-Gil), flopitz@cicbiogune.es (F. Lopitz-Otsoa), rfarras@cipf.es (R. Farrás), n.r.e.hjerpe@dundee.ac.uk (R. Hjerpe), monica.atorres@gmail.com (L. Torres-Ramos), lzabaleta@inbiomed.org (L. Zabaleta), christine.blattner@kit.edu (C. Blattner), r.t.hay@dundee.ac.uk (R.T. Hay), rbarrio@cicbiogune.es (R. Barrio), acarracedo@cicbiogune.es (A. Carracedo), juanf@bsc.es (J. Fernandez-Recio), msrodriguez@inbiomed.org (M.S. Rodríguez), faillet@inbiomed.org (F. Aillet).

¹ Present address: The MRC Protein Phosphorylation and Ubiquitylation Unit, The Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland.

² Present address: Instituto Nacional de Neurología y Neurocirugía “Manuel Velasco Suárez”, México D.F., Mexico.

1574-7891/\$ – see front matter © 2014 Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.

<http://dx.doi.org/10.1016/j.molonc.2014.04.002>

Please cite this article in press as: Lang, V., et al., Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity, *Molecular Oncology* (2014), <http://dx.doi.org/10.1016/j.molonc.2014.04.002>

Accepted 2 April 2014

Available online ■

Keywords:

p53

Ubiquitylation

Oligomerization

Transcription

Proteasome

proteasome-mediated degradation. However, mutants unable to form tetramers are well degraded by the 20S proteasome. Unexpectedly, despite the lower structural stability compared to WT p53, p53 OD mutants form heterotetramers with WT p53 when expressed transiently or stably in cells wild type or null for p53. In consequence, p53 OD mutants interfere with the capacity of WT p53 tetramers to be properly ubiquitylated and result in changes of p53-dependent protein expression patterns, including the pro-apoptotic proteins Bax and PUMA under basal and adriamycin-induced conditions. Importantly, the patient derived p53 OD mutant L330R (OD1) showed the more severe changes in p53-dependent gene expression. Thus, in addition to the well-known effects on p53 stability, ubiquitylation defects promote changes in p53-dependent gene expression with implications on some of its functions.

© 2014 Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.

1. Introduction

The tumor suppressor p53 is a major gatekeeper of the genome that tightly controls critical processes in the cell, acting as a central player within a large network of proteins involved in DNA-repair, apoptosis or cell cycle (Levine, 1997; Vogelstein et al., 2000; Zilfou and Lowe, 2009). P53 is a transcription factor that binds its DNA consensus sequence as a tetramer to activate transcription. The C-terminus of p53 contains the oligomerization domain (OD) that is required for the formation of the transcriptionally active tetramer. The C-terminus also contains sub-cellular localization signals and amino acids targeted by a wide variety of posttranslational modifications, including phosphorylation, acetylation, methylation, SUMOylation (Alarcon-Vargas and Ronai, 2002; Chuikov et al., 2004; Rodriguez et al., 1999) and ubiquitylation that control its degradation by the 26S proteasome (Maki, 1999; Rodriguez et al., 2000) and its function (Funk et al., 1992; Maki and Howley, 1997; Maltzman and Czyzyk, 1984). Data from *in vivo* experiments in mouse models have suggested that ubiquitylation of lysines located in C-terminal may play a role in the regulation of transcriptional activity in a manner of “fine-tuning” the expression of specific p53-dependent genes (Krummel et al., 2005) (Feng et al., 2005). Among the most important p53-dependent genes, the ubiquitin protein-ligase Mdm2, has been shown to be crucial for regulation of p53 function (Fang et al., 2000) and its proteasomal degradation (Chowdary et al., 1994; Maki, 1999; Maki et al., 1996). Other well-known p53-target-genes are Bax, PUMA, Noxa, Bid, Fas/CD95, which are involved in apoptosis, while p21 and E2F1 control cell cycle arrest and proliferation (Riley et al., 2008).

P53 is found mutated in about half of human cancers (Hollstein et al., 1991; Soussi and Beroud, 2001) with most of the mutations being missense and mainly located in the core DNA-Binding domain. To date, the database of TP53 maintained at IARC, has registered more than 30,000 mutations in humans (www-p53.free.fr/www-p53.iarc.fr) (Olivier et al., 2002). Few mutations have been registered in its OD (Milner and Medcalf, 1991; Sturzbecher et al., 1992). After epidemiologic studies, 17% of germline mutations in patients with Li-Fraumeni syndrome occurred in the p53 OD (Petitjean et al., 2007). Transcriptionally silent p53 mutants generate transdominant negative effects over a WT allele through mechanisms that are not well understood. The aberrant

accumulation of mutant p53 in tumor cells suggests an alteration in its degradation pathway. Intrigued by these aspects, we have introduced single point mutations in the β -strand of the p53 OD, mimicking the alterations in L330 observed in cancer, which is one of the crucial amino acids for correct tetramerization (Chene and Bechter, 1999). NMR and X-Ray crystallography analysis revealed that OD (residues 323–356) contains one β -strand (326–333) and one α -helix (335–354) with a V-shaped structure (Chene, 1997; Clore et al., 1995; Jeffrey et al., 1995; Lee et al., 1994; Miller et al., 1996; Mittl et al., 1998). The hydrophobic amino-acid L330 together with seven other residues (F328, I332, R337, F338, F341, N345 and D352) form a critical hydrophobic pocket, allowing association of two dimers, necessary for the formation of a transcriptionally active tetramer and for preservation of p53 stability (Clore et al., 1995; Friedman et al., 1993; Jeffrey et al., 1995; Kato et al., 2003; Kawaguchi et al., 2005; Mateu and Fersht, 1998).

2. Materials and methods

2.1. Modeling of the p53 dimer structure by docking simulation

We used the monomeric structure of the p53tet PDB 1AIE; 1.5 Å in its active tetrameric form as starting structure for the WT dimer model and as scaffold to build all the structures of the mutants described herein, using SCWRL3.0 program (Canutescu et al., 2003). The rigid-body docking simulations were performed using the FFT-based docking program FTDOCK with grid resolution of 0.7 Å and electrostatics (Gabb et al., 1997), which generated a set of 10,000 docking poses that were evaluated by the energy-based pyDock scoring scheme (Cheng et al., 2007). For each docking run, we selected the lowest-energy solution. RMSD was calculated for a monomer respect to its equivalent in the p53 dimer structure (as found in the p53 biological assembly) after superposition of the interacting partner monomer.

2.2. Molecular dynamics simulation of WT and mutant p53 dimer structures

The WT p53 dimer structure for the Molecular dynamics (MD) simulation was extracted from PDB code 1AIE. The mutants were built *in silico* from the WT structure, using the AMBER

Download English Version:

<https://daneshyari.com/en/article/10914642>

Download Persian Version:

<https://daneshyari.com/article/10914642>

[Daneshyari.com](https://daneshyari.com)